Elanco Animal Health Incorporated (BMV:ELAN)
Mexico · Delayed Price · Currency is MXN | Market Cap | 198.71B +89.5% |
| Revenue (ttm) | 84.89B +6.2% |
| Net Income | -4.18B |
| EPS | -8.46 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 22.02 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 533 |
| Average Volume | 539 |
| Open | 399.50 |
| Previous Close | 262.00 |
| Day's Range | 392.00 - 399.50 |
| 52-Week Range | 246.50 - 399.50 |
| Beta | n/a |
| RSI | n/a |
| Earnings Date | May 8, 2026 |
About Elanco Animal Health
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal fam... [Read more]
News
Elanco Launches Advantage™ Collar for Dogs with Four Months of Continuous Protection from Fleas, Ticks and Mosquitoes*
Breaks the flea lifecycle* with Pyriproxyfen, an insect growth regulator, preventing fleas from reinfesting the dog Adjustable collar fits comfortably and securely on a dog of any size Strengthens Ela...
Elanco Animal Health Reports Fourth Quarter and Full Year 2025 Results
Raising 2026 Innovation Target; Full Year 2026 Guidance of 4%-6% Organic Constant Currency Revenue Growth, 6%-9% Adjusted EBITDA Growth In Line with Investor Day Outlook Fourth Quarter 2025 Financial ...
Elanco to Participate in Upcoming Investor Conferences
INDIANAPOLIS, Ind., Feb. 19, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.
Elanco Announces Updates to Board of Directors
INDIANAPOLIS, Feb. 13, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to its Board of Directors. R. David Hoover and Deborah Kochevar will not stand for re...
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco w...
Elanco to Participate in the 44th Annual J.P. Morgan Healthcare Conference
INDIANAPOLIS, Jan. 6, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026.
Elanco Receives USDA Approval for Befrena™ (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis
Elanco's second dermatology product approval in less than 18 months in the estimated $1.3 billion U.S. canine dermatology market Befrena has been shown to be effective for treatment of dogs of any age...
Elanco's Credelio Quattro™-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Receives First FDA Conditional Approval for Treatment of New World Screwworm in Dogs
Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's Conditional A...
Jim Cramer Praises Elanco Animal Health: 'They've Turned That Company Around'
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Elanco Animal Health Incorporated (NYSE: ELAN).
Animal Health Focused Elanco Details Pipeline Momentum, US Investments, Cost-Saving Plans
On Tuesday, Elanco Animal Health Incorporated (NYSE: ELAN) used its first Investor Day in five years to signal a turning point for the company, outlining a more focused strategy aimed at sustainable g...
Elanco Investor Day Defines New Era as Sustainable Growth Company
Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and lo...
Elanco executive appointed as Neurizon's Board Observer
MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advanc...
Elanco's drug gets emergency nod to treat deadly flesh-eating parasite in cats
The U.S. Food and Drug Administration on Friday authorized emergency use of Elanco Animal Health's chewable tablet to treat the infestation of a parasite in cats known as New World screwworm.
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats
EUA to Treat Cats for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First U.S. Food and Drug Administration Emergency Use Auth...
Elanco Animal Health Stock Is Undervalued: Analyst
As the pet care industry experiences rapid growth, pharmaceutical companies are increasingly focusing on developing innovative treatments for companion animals.
Elanco to Participate in the Upcoming Investor Conferences
INDIANAPOLIS , Nov. 20, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences. On Wednesday, December 3,...
Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health
Alloy Partners, Elanco and other corporate partners join forces to develop new venture studio INDIANAPOLIS , Nov. 13, 2025 /PRNewswire/ -- Alloy Partners today announced the launch of OneHealth Studio...
Elanco Animal Health CEO: Seeing a willingness to spend, durability even in 'consumer tested' time
Jeff Simmons, Elanco Animal Health CEO, joins 'The Exchange' to discuss what's driving the company's earnings results, where the company's is devoting the most resources and much more.
Elanco Animal Health Reports Third Quarter 2025 Results
Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Third Quarter 2025 Financial Results: Revenue of $1,137 million, an increase of 10% year-over-year; 9% org...
Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species
FDA approves expanded Credelio Quattro and Credelio labels to include prevention of Lyme disease as a result of killing black-legged ticks (lxodes scapularis) and protection against the longhorned tic...
Elanco gets US FDA emergency nod for dog drug as threat of flesh-eating parasite looms
Elanco Animal Health said on Friday it had received an emergency use authorization from the U.S. Food and Drug Administration for its flea and tick drug to treat dogs infected with a flesh-eating para...
Elanco Animal Health Obtains FDA Authorization for Screwworm Treatment
Health and Human Services Secretary Robert F. Kennedy Jr. determined that New World screwworm presents significant potential for a public health emergency.
Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
EUA to Treat Dogs for NWS Issued Prior to Fly Being Detected in the U.S.; Action Prepares Veterinarians and Pet Owners with Treatment Options First FDA emergency use authorization (EUA) ever granted f...
Elanco to Host Investor Day on December 9
INDIANAPOLIS , Oct. 16, 2025 /PRNewswire/ -- Elanco Animal Health, Inc. (NYSE: ELAN) will host an Investor Day on Tuesday, December 9, 2025, from approximately 9 a.m. to 12 p.m.